Financings in Brief: Vidamed
This article was originally published in The Gray Sheet
Executive Summary
Vidamed: Files with the Securities and Exchange Commission for the issuance of up to 950,000 shares of common stock that will enable the firm to complete a financing arrangement with Dutch merchant bank MeesPierson worth up to $10 mil. The funds are tabbed for working capital to launch the Menlo Park, California firm's TUNA transurethral needle ablation system for treatment of benign prostatic hyperplasia. The system was cleared via 510(k) in October 1996 ("The Gray Sheet" Oct. 14, 1996, I&W-4)...
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.